Alyeska Investment Group’s Theriva Biologics TOVX Stock Holding History

Alyeska Investment Group’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-20,000	Closed	-$2.56M	–	582
2020 Q2	$2.56M	Hold	20,000	–	–	0.04%	339
2020 Q1	$1.61M	Hold	20,000	–	–	0.03%	270
2019 Q4	$2.54M	Hold	20,000	–	–	0.03%	279
2019 Q3	$2.27M	Hold	20,000	–	–	0.03%	283
2019 Q2	$2.75M	Hold	20,000	–	–	0.04%	292
2019 Q1	$3.4M	Hold	20,000	–	–	0.04%	248
2018 Q4	$2.8M	Hold	20,000	–	–	0.04%	268
2018 Q3	$13M	Buy	20,000 +19,429	+3,403%	+$21.5M	0.14%	163
2018 Q2	$1.2M	Hold	571	–	–	0.01%	387
2018 Q1	$1.59M	Hold	571	–	–	0.01%	366
2017 Q4	$2.54M	Sell	571 -572	-50%	-$3.57M	0.02%	315
2017 Q3	$9.33M	Hold	1,143	–	–	0.07%	249
2017 Q2	$5.66M	Hold	1,143	–	–	0.05%	276
2017 Q1	$6.31M	Hold	1,143	–	–	0.05%	290
2016 Q4	$7.63M	Buy	+1,143	New	+$11.7M	0.06%	296

Other funds holding TOVX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Alyeska Investment Group's TOVX Position: Q4 2017 in Review

Alyeska Investment Group sold out of Theriva Biologics (TOVX) in Q4 2017, closing a stake of 201 shares — an estimated $1.26M sold.

Alyeska Investment Group first reported a position in TOVX in Q3 2015 and held it in 5 quarters. The position peaked at $3.5M in Q4 2016. 48 funds tracked by Wall St. Rank hold TOVX as of Q4 2017.

Alyeska Investment Group reported no remaining Theriva Biologics position as of Q4 2017 after selling out during the quarter.
Alyeska Investment Group sold 201 Theriva Biologics shares in Q4 2017, an estimated $1.26M.
Alyeska Investment Group first reported a position in Theriva Biologics in Q3 2015 and held it in 5 quarters.
Alyeska Investment Group's Theriva Biologics position peaked at $3.5M in Q4 2016.
48 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2017.

Based on Alyeska Investment Group's 13F filing for Q4 2017, filed 14 Feb 2018.